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Abstract
Diabetes constitutes a major health challenge. Since cardiovascular complications are common in diabetic patients this will
further increase the overall burden of disease. Furthermore, stress-induced hyperglycemia in non-diabetic patients with
acute myocardial infarction is associated with higher in-hospital mortality. Previous studies implicate oxidative stress,
excessive flux through the hexosamine biosynthetic pathway (HBP) and a dysfunctional ubiquitin-proteasome system (UPS)
as potential mediators of this process. Since oleanolic acid (OA; a clove extract) possesses antioxidant properties, we
hypothesized that it attenuates acute and chronic hyperglycemia-mediated pathophysiologic molecular events (oxidative
stress, apoptosis, HBP, UPS) and thereby improves contractile function in response to ischemia-reperfusion. We employed
several experimental systems: 1) H9c2 cardiac myoblasts were exposed to 33 mM glucose for 48 hr vs. controls (5 mM
glucose); and subsequently treated with two OA doses (20 and 50 mM) for 6 and 24 hr, respectively; 2) Isolated rat hearts
were perfused ex vivo with Krebs-Henseleit buffer containing 33 mM glucose vs. controls (11 mM glucose) for 60 min,
followed by 20 min global ischemia and 60 min reperfusion 6 OA treatment; 3) In vivo coronary ligations were performed
on streptozotocin treated rats 6 OA administration during reperfusion; and 4) Effects of long-term OA treatment (2 weeks)
on heart function was assessed in streptozotocin-treated rats. Our data demonstrate that OA treatment blunted high
glucose-induced oxidative stress and apoptosis in heart cells. OA therapy also resulted in cardioprotection, i.e. for ex vivo
and in vivo rat hearts exposed to ischemia-reperfusion under hyperglycemic conditions. In parallel, we found decreased
oxidative stress, apoptosis, HBP flux and proteasomal activity following ischemia-reperfusion. Long-term OA treatment also
improved heart function in streptozotocin-diabetic rats. These findings are promising since it may eventually result in novel
therapeutic interventions to treat acute hyperglycemia (in non-diabetic patients) and diabetic patients with associated
cardiovascular complications.
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Introduction
The dramatic surge in diabetes during the past few decades
constitutes a major threat to human health in developed and
developing nations [1,2]. Since cardiovascular complications and
mortalities are common in diabetic patients [3,4], this will further
increase the overall burden of disease. These alarming projections
therefore necessitate a comprehensive understanding of the
underlying molecular mechanisms orchestrating the onset of
cardiovascular diseases (CVD) in diabetic individuals.
Diabetes is characterized by perturbed metabolic pathways
usually resulting in hyperlipidemia, hyperinsulinemia and hyper-
glycemia. Cardiovascular complications frequently present in
diabetic patients and chronic hyperglycemia is an important risk
factor for myocardial infarction [5,6]. Moreover, stress-induced,
acute hyperglycemia in non-diabetic patients with acute myocar-
dial infarction is associated with increased in-hospital deaths [7,8].
Acute and chronic hyperglycemia trigger biochemical and
electrophysiological changes that may result in impaired cardiac
contractile function [9]. Moreover, hyperglycemia also generates
reactive oxygen species (ROS) and cell death in the myocardium,
thereby contributing to the onset of CVD [10–13]. For example,
we previously found that hyperglycemia-induced ROS increased
flux through the hexosamine biosynthetic pathway (HBP) leading
to greater O-GlcNAcylation of target proteins and myocardial
apoptosis [13,14]. Hyperglycemia-induced oxidative stress can
also result in the formation of misfolded or damaged proteins that
may be eliminated by the ubiquitin-proteasome system (UPS).
Previous studies revealed dysfunctional UPS with hyperglycemia,
linked to greater inflammation and attenuated cardiac function at
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baseline and in response to ischemia-reperfusion [10,15]. Howev-
er, it remains unclear whether increased or decreased UPS is
detrimental with hyperglycemia and/or in response to ischemia-
reperfusion. For example, Pye et al. [16] found that myocardial
reperfusion injury is reduced by proteasomal inhibitors, while
others determined that UPS overactivity may enhance the risk of
complication during myocardial ischemia in diabetic patients [10].
Conversely, Bulteau et al. [17] established that proteasomal
impairment may contribute to the detrimental effects of myocar-
dial ischemia. Additional studies are therefore required to
determine the mechanisms underlying dysfunctional UPS in the
heart under these conditions.
Despite the prevalence of commercially-available drugs used to
treat diabetes, the use of alternative, plant-derived medicines is
gaining momentum [18]. For example, earlier studies evaluated
the anti-diabetic therapeutic potential of Syzygium aromaticum
[(Linnaeus) Merrill & Perry], belonging to the family Myrtaceae
(commonly referred to as cloves). Here research workers estab-
lished that its active constituent is the triterpenoid, oleanolic acid
(OA), displaying anti-hyperglycemic properties [19–21]. Further-
more, OA exhibited cardioprotective properties in response to
ischemia-reperfusion by upregulation of myocardial anti-oxidant
defenses [22,23]. In light of this, we hypothesized that OA
possesses anti-oxidant and anti-apoptotic properties and is thus
able to blunt acute and chronic hyperglycemia-mediated patho-
Figure 1. OA treatment attenuates oxidative stress in H9c2 cells. Quantification of oxidative stress (DCFDA staining) in H9c2 cells in response
to simulated chronic hyperglycemia (33 mM glucose) vs. control (5.5 mM glucose)6 treatment with 20 mM or 50 mM OA for 6 and 24 hr, respectively.
(A) and (C) Fluorescence microscopy; (B) and (D) Flow cytometry. Values are expressed as mean 6 SEM (n= 9). *p,0.05, **p,0.01, ***p,0.001 vs.
respective controls.
doi:10.1371/journal.pone.0047322.g001
Figure 2. Decreased apoptotic cell death in H9c2 cells treated
with OA (caspase activity). Evaluation of caspase activity in H9c2
cells in response to simulated chronic hyperglycemia vs. control 6
treatment with 20 mM and 50 mM OA, respectively, for 24 hr. Values are
expressed as mean 6 SEM (n= 9). ***p,0.001 vs. respective controls.
doi:10.1371/journal.pone.0047322.g002
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physiologic sequelae within the rat heart. Moreover, we proposed
that OA attenuates the myocardial UPS and HBP, and thereby
improves cardiac contractile function in response to ischemia-
reperfusion under hyperglycemic conditions.
Materials and Methods
Isolation of Oleanolic Acid from Clove Extract
We employed Syzygium aromaticum [(Linnaeus) Merrill & Perry]
(Myrtaceae) cloves (Africa International Food and Cosmetics
Technologies, Durban, South Africa) to isolate and purify OA for
this study. This approach was adopted since it generates sufficient
amounts of OA in a cost-effective manner compared to purchasing
purified OA on a regular basis. Cloves (1 kg) were extracted at
room temperature for 24 hr sequentially in 3 liters of each,
dichloromethane and ethyl acetate. This step was repeated 3 times
to yield residues of dichloromethane-solubles and ethyl acetate-
solubles (EAS), respectively. Previous studies demonstrated that
OA is mostly concentrated in the latter fraction [21]. Subsequent-
ly, filtration was performed with 30 cm filter paper (Whatman
International Ltd, Maidstone, England) where after filtrates were
concentrated in vacuo using a rotary evaporator (Boeco, Hamburg,
Germany) at 60uC. This procedure resulted in the isolation of a
crude ethyl-acetate extract.
To identify chemical constituents, crude ethyl-acetate extracts
were thereafter analyzed by thin layer chromatography (TLC) on
pre-coated aluminium plates using Silica Gel 60 F254 (Merck,
Darmstadt, Germany). Here we spotted a diluted portion of the
isolated, crude extract and compared this with commercially
obtained OA (Sigma-Aldrich, St Louis, MO). After developing the
TLC plate with ethyl acetate/hexane (7:3), it was exposed to
ultraviolet light (254–366 nm), sprayed with anisaldehyde/sulphu-
ric acid/alcohol solution and the TLC plate subsequently dried
with hot air. The appearance of a blue/violet-blue coloration
indicated the presence of triterpenoids [23,24].
Since the EAS fraction of S. aromaticum contained triterpenoids,
it was subjected to further purification processes. We fractionated
2 g of EAS on silica gel (70–230 mesh, 3.5645 cm) by open
column chromatography with a ratio of 7:3 ethyl acetate and
hexane, respectively. An aliquot of each collected fraction was
then subjected to TLC as before, and compared to commercially
obtained OA. This allowed us to pool the remainder of collected
fractions according to TLC profiles (i.e. similar to OA), which was
thereafter concentrated in vacuo using a rotary evaporator (Boeco,
Hamburg, Germany) at 55uC. Concentrates were reconstituted
using minimal amounts of chloroform and crystallized OA allowed
to air dry. We re-crystallized OA with ethanol and its structure was
confirmed by spectroscopic analysis using 1D and 2D 1H and 13C
nuclear magnetic resonance techniques to a purity of,98%. For a
small part of this study we also employed commercially available
OA (Sigma-Aldrich, St. Louis, MO) due to logistic reasons.
Cell Culture and Oleanolic Acid Treatments
H9c2 rat cardiomyoblasts (ECACC No. 88092904) were
maintained at 37uC (5% CO2 and 95% humidity) in low glucose
(5.5 mM) Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich, St. Louis, MO) supplemented with 10% fetal bovine
serum (Invitrogen, Carlsbad, CA) as described before by us [13].
On the first day, H9c2 cells were split, sub-cultured and allowed to
plate for 24 hr. Cells were thereafter cultured in DMEM
containing: 5.5 mM glucose (control group), or 33 mM glucose
(high glucose). With the high glucose exposure we attempted to
simulate chronic hyperglycemia in our cell-based studies. H9c2
cells were cultured for an additional 48 hr under these conditions
followed by dose-dependent treatment with 0, 20, 50 mMOA for 6
and 24 hr, respectively. The doses were selected based on
literature [25,26].
Measurement of Intracellular ROS Levels and Apoptosis
Intracellular ROS levels were determined by immunofluores-
cence microscopy as previously described [13]. Briefly, cells were
grown in special chamber slides and treated with OA as described
above. Subsequently, live cells were incubated with 29,79-
dichlorodihydrofluorescein diacetate (DCFDA) stain (1:200; In-
vitrogen, Carlsbad, CA) for 10 min at 37uC (in the dark). The cells
were then further stained with Hoechst dye in PBS at a ratio of
1:200 for 3–5 min. Stains were then washed off, and cells were
visualized using an Olympus CellˆR fluorescence 1681 inverted
microscope (Olympus Biosystems, Planegg, Germany) with an F-
view II camera for image acquisition and CellˆR software for
processing images. The temperature of the microscope was
maintained at 37uC for live cell imaging using a Solent Scientific
microscope incubator chamber (Solent Scientific, Segensworth,
UK). Three independent experiments were conducted and at least
3 images per experiment analyzed.
We also measured ROS levels by flow cytometry. After
treatment, cells were trypsinized and centrifuged (2 min at
20,000 g), and the cell pellet treated with 29,79-dichlorodihydro-
fluorescein diacetate stain (1:200), resuspended, and incubated at
37uC for 20 min in the dark. Cells not treated with 29,79-
dichlorodihydrofluorescein diacetate acted as negative controls,
and stained cells treated with 100 ml hydrogen peroxide (30% w/v
hydrogen peroxide) incubated for 10 min served as positive
controls. ROS levels were measured using a flow cytometer
(Becton-Dickinson, Franklin Lakes, NJ) and quantified by deter-
mining the mean of fluorescence for each treatment. Three
independent experiments were conducted for each condition
investigated, with typically 5,000–10,000 cells analyzed per
experiment.
In a separate set of experiments, we evaluated apoptosis by
employing a caspase activity assay (Promega, Madison, WI).
Briefly, H9c2 myoblasts were trypsinized, counted in a hemocy-
tometer and ,16104 cells seeded per well of a 96-well plate
(Greiner, Kremsmu¨nster, Austria). Cells were seeded with 300 ml
DMEM. DMEM was removed from cells and 100 ml of the
reconstituted assay reagent added into each well and gently mixed.
Cells were subsequently incubated for ,2 hr at room temperature
and the degree of luminescence measured in white walled 96-well
luminometer plates (Amersham, Buckinghamshire, UK).
We further confirmed our apoptosis data by employing an
Annexin V-FITC kit (MACS, Miltenyi Biotec, Germany) accord-
ing to the manufacturer’s instructions. In brief, 100 mM OA was
administered for 6 and 24 hr, respectively, as before (refer ‘Cell
culture and OA treatments’ section). After the completion of our
experimental protocol, cells were washed with sterile PBS (calcium
free), trypsinized and centrifuged at 300 g for 3 min. The pellet
was washed with 1 ml of 1x binding buffer per 106 cells and re-
centrifuged at 300 g for 3 min. The resulting pellet was
resuspended in 100 ml of 1x binding buffer per 106 cells and
thereafter incubated with 10 ml of Annexin V-FITC for 15 min in
the dark at room temperature. Cells were subsequently washed
with 1 ml of 1x binding buffer and centrifuged at 300 g for 3 min.
The pellet was resuspended in 500 ml of 1x binding buffer and 5 ml
of PI solution immediately added, prior to analysis by flow
cytometry. Viable cells (annexin V2PI2); non-viable, including
late apoptotic or necrotic cells (Annexin V+PI+) or Annexin
V2PI+) and apoptotic cells (Annexin V+PI2) were detected by the
inding of Annexin V to externalized phosphatidylserine in
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conjuction with PI. Results are presented as the percentage of
apoptosis normalized to control (ratio of early apoptotic,
Annexin+/PI2 cells to the total population).
Animals and Ethics Statement
All animals were treated in accordance with the Guide for the
Care and use of Laboratory Animals of the National Academy of
Sciences (NIH publication No. 85–23, revised 1996). Studies were
performed with the approval of the Animal Ethics Committees of
Stellenbosch University and the University of Cape Town (South
Africa), and the United Arab Emirates University (United Arab
Emirates).
Ex vivo Global Ischemia during Simulated Acute
Hyperglycemia
These studies were carried out at Stellenbosch University (South
Africa). Male Wistar rats weighing 180–220 gr were used
throughout the study. Rats were anesthetized (pentobarbitone,
100 mg/kg i.p) and hearts rapidly excised and perfused in a
modified Langendorff model with Krebs-Henseleit buffer equili-
brated with 95% O2–5% CO2 (37uC, pH 7.4) at a constant
pressure (100 cm). The Krebs-Henseleit buffer contained (in mM)
11 Glucose, 118 NaCl, 4.7 KCl, 1.2 MgSO4.7H2O, 2.5
CaCl2.2H2O, 1.2 KH2PO4, 25 NaHCO3. Hearts were randomly
distributed into four experimental groups: 1) control (11 mM
glucose), untreated; 2) control (11 mM glucose), OA treated; 3)
high glucose (33 mM glucose), untreated and 4) high glucose
(33 mM glucose), OA treated (n= 9 for each group). With the high
glucose perfusions we are attempting to simulate acute hypergly-
cemia within the clinical setting. Moreover, since ex vivo
Langendorff perfusions are typically performed with 11 mM
glucose at baseline, we are of the opinion that the 33 mM dose is
representative of a 3-fold elevation of glucose levels (above normal)
within the clinical setting.
The protocol was divided into two parts, i.e. perfusions a)
without ischemia and b) with ischemia and reperfusion. For the
non-ischemic protocol, we stabilized for 60 min whereafter
100 mM OA was added to the perfusate for an additional
20 min period. Subsequently, we returned the buffer used in the
stabilization period and perfused for a further 20 min (total
perfusion time: 100 min). For the ischemic protocol, 100 mM OA
was added during the first 20 min of reperfusion (for OA
experimental groups only; refer details below). OA was dissolved
in a small volume of DMSO and less than 0.0005% (v/v) DMSO
was present during perfusion experiments.
During perfusion, a latex balloon attached to a pressure
transducer (Stratham MLT 0380/D, AD Instruments Inc., Bella
Vista, NSW, Australia) compatible with the PowerLab System
ML410/W (AD Instruments Inc., Bella Vista, NSW, Australia),
was inserted into the left ventricle and inflated to produce a
diastolic pressure of 4–12 mm Hg. The protocol had a 60 min
stabilization period, 20 min of global ischemia, followed by
reperfusion for a further 60 min. Contractile parameters assessed
included heart rate (HR), left ventricular developed pressure
(LVDP), and rate-pressure product (RPP; RPP=HR6LVDP).
Left ventricular tissues were collected at 4 time points, i.e. a) within
the first two min after ischemia, b) 20 and c) 40 min after ischemia,
respectively, and d) also after 60 min of reperfusion. Collected
Figure 3. Diminished apoptosis in OA-treated H9c2 cells (flow cytometry). Flow cytometric analysis using the Annexin V/FITC apoptosis
assay kit to evaluate the effects of 100 mM OA treatment under control and high glucose culturing conditions (24 hr). (A), (B), (C) and (D)
Representative FACS analyses of four individual experiments corresponding to control and high glucose 6 OA treatment, respectively. (E) and (F)
Quantification of OA treatment after 6 and 24 hr, respectively. Values are normalized to the control and expressed as mean6 SEM (n= 4). ***p,0.001
vs. controls and ##, ### p,0.01, p,0.001 vs. high glucose exposure without OA treatment.
doi:10.1371/journal.pone.0047322.g003
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tissues were freeze-clamped in liquid nitrogen and stored at
280uC for further analysis.
Ex vivo Regional Ischemia during Simulated Acute
Hyperglycemia
These studies were carried out at Stellenbosch University (South
Africa). To further strengthen our Langendorff perfusion data we
also evaluated the effects of OA by infarct size determination. This
was performed as described before but with slight modifications
[27], i.e. we employed regional ischemia with a reperfusion time of
2 hr. Here a 3/0 silk suture was placed on the proximal portion of
the left anterior descending coronary artery and passing the ends
through a plastic tube. For induction of regional ischemia, the ends
were tightened by pressing the plastic tube against the surface of
the heart (above the artery) for 20 min. The snare was released
during the reperfusion period. The efficacy of ischemia was
confirmed by regional cyanosis and a substantial decrease in
coronary flow.
Determination of Infarct Size
After completion of each regional ischemia-reperfusion exper-
iment the snare was re-tightened and 2.5% Evans Blue dye (in
Krebs buffer) was perfused through the hearts for infarct
development. Hearts were subsequently removed from the
Langendorff apparatus, blotted dry, suspended within 50 ml
plastic tubes (using suture) and frozen at 220uC for 3 days.
Thereafter, frozen hearts were sliced into 2 mm transverse sections
and incubated with 1% 2,3,5-triphenyl tetrazolium chloride (TTC)
in phosphate-buffered saline for 20 min at 37uC to identify non-
infarcted (stained) from infarcted (non-stained) tissues. Slices were
then fixed in 10% formalin for 24 hr at room temperature before
being placed between glass plates for scanning (both sides). The
infarct area (IA) size and the area at risk (AAR) were calculated
using Image J software (v1.46p, National Institutes of Health,
USA). Values of tissue slices were added together in order to
obtain the total IA and AAR for each heart analyzed. We
expressed the infarct size as the ratio of IA versus the AAR (%IA/
AAR).
Figure 4. OA treatment does not affect pre-ischemic cardiac function. Isolated rat hearts were perfused under simulated hyperglycemic
conditions (33 mM glucose) vs. controls (11 mM glucose) 6100 mM OA treatment. We initially perfused for 60 min, whereafter OA was added for a
further 20 min. Subsequently, the buffer initially used was returned and hearts perfused for an additional 20 min. (A) Left ventricular developed
pressure at baseline (11 mM) and (B) high glucose conditions (33 mM). Rate pressure product (RPP) at baseline (C) and (D) high glucose levels. Values
are expressed as mean 6 SEM (n= 9).
doi:10.1371/journal.pone.0047322.g004
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Figure 5. OA treatment blunts high glucose-induced cardiac dysfunction following ischemia and reperfusion. Isolated rat hearts were
perfused under simulated hyperglycemic conditions (33 mM glucose) vs. controls (11 mM glucose) and subjected to 20 min of global ischemia,
followed by 60 min of reperfusion. For OA treatments groups, 100 mM OA was added during the first 20 min of reperfusion. (A) Left ventricular
developed pressure (% recovery) at baseline glucose levels (11 mM), and (B) with high glucose (33 mM). Rate pressure product (RPP) at baseline
glucose levels (C), and (D) under high glucose conditions. Values are expressed as mean 6 SEM (n= 9).*p,0.05, ***p,0.001 vs. respective controls.
doi:10.1371/journal.pone.0047322.g005
Figure 6. OA administration decreases infarct size under high
glucose perfusion conditions. Isolated rat hearts were perfused
under high glucose conditions vs. controls and subjected to regional
ischemia. For OA treated groups, 100 mM OA was added during the first
20 min of the two hr reperfusion period. Evans blue dye and TTC
staining enabled visualization of viable tissue (blue), infarcted area
(white) and the area at risk (red). Values are expressed as mean 6 SEM
(n = 6). *p,0.05, ***p,0.001 vs. respective controls.
doi:10.1371/journal.pone.0047322.g006
Figure 7. OA treatment decreases infarct size following
coronary artery ligation in streptozotocin-diabetic rats. Wistar
rats were injected with STZ and followed for a 1-week period.
Subsequently, 0.45 mg/kg OA was injected via the penile vein within
the first two min of reperfusion. Evans blue dye and TTC staining
enabled visualization of viable tissue (blue), infarcted area (white) and
the area at risk (red). Values are expressed as mean 6 SEM (n= 6).
*p,0.05, **p,0.01 vs. respective controls.
doi:10.1371/journal.pone.0047322.g007
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In vivo Regional Ischemia during Chronic Hyperglycemia
(Streptozotocin-treated Rats)
We next tested the effects of OA on diabetic rats (chronic
hyperglycemia) subjected to an ischemic insult. These experiments
were completed at the University of Cape Town (South Africa).
Hyperglycemia was induced in Wistar rats as previously described
[21,25]. In brief, male Wistar rats weighing 250–300 gr were
injected (intraperitoneally) with a single dose of streptozotocin
(STZ) (60 mg/kg dissolved in freshly prepared 0.1 M citrate buffer
[pH 6.2]; Sigma-Aldrich, St Louis MO). Control rats were
injected with the vehicle (citrate buffer). Blood glucose concentra-
tions of $20 mmol/l after 1 week were considered as a stable
diabetic state before experimental procedures. We also determined
body weights and non-fasting blood glucose levels before STZ
induction and after the one week of diabetes induction.
For the in vivo coronary artery ligation experiments, rats were
divided into control (citrate-treated) and diabetic (STZ-treated)
groups. Each group was subjected to coronary artery ligations 6
OA treatment (0.45 mg/kg i.v) (as described in detail below). The
OA was dissolved in ,0.001% DMSO and deionized water;
freshly done for each treatment period.
Ligation experiments were performed one week after STZ
intraperitoneal injection and confirmation of a stable diabetic
state. Rats were anesthetized with sodium pentobarbital (60 mg/
kg i.p.), intubated, and thereafter ventilated with room air
(2.5 ml/stroke) at a rate of 75 strokes per min via a rodent
ventilator (Model 681, Harvard Apparatus, USA). Body temper-
ature was monitored by a rectal temperature probe and a
constant temperature was maintained throughout the surgical
procedure by placing rats on a custom-made heating block. The
depth of anesthesia was checked by assessing the pedal
withdrawal reflex and by monitoring heart rate. Maintenance
doses of anesthetic (6 mg/kg i.p) were administered as required.
Lead II electrocardiogram (ECG) was recorded via an Animal
Bio Amplifier (ML136, ADInstruments, Castle Hill, New South
Wales, Australia). Carotid arterial blood pressure was recorded
via a custom-made cannula attached to a pressure transducer
(MLT0670, ADInstruments, Castle Hill, New South Wales,
Australia). Since formation of clots around intra-arterial cannulae
poses a potential risk for arterial thrombosis, heparin (1000 IU/
kg i.p) was injected concurrently with anesthetic [28,29].
A left thoracotomy was performed through the 4th intercostal
space and the left lung collapsed using a damp swab. The left
anterior descending coronary artery was thereafter ligated as
previously described [30]. A 6–0 silk suture was placed around the
left anterior descending coronary artery and its ends passed
through a plastic tube. For induction of regional ischemia the ends
of the suture were used as a snare to occlude the artery by applying
it gently onto the ventricular surface for 30 min. The efficacy of
ischemia was confirmed by regional cyanosis and ECG changes.
We employed S-T elevation (ECG) to confirm coronary artery
ligation. The snare was released during reperfusion.
Rat hearts were subjected to 30 min ischemia followed by 2 hr
of reperfusion. The penile vein was cannulated for OA
administration, while the vehicle solution was administered to
control animals. For the OA rats, a bolus dose of 0.45 mg/kg i.v
[21] was injected immediately on reperfusion (within 1 min of
releasing the snare) and therafter reperfused for 2 hr as before.
After the reperfusion period, the heart was flushed with saline
and the coronary artery was re-occluded with the suture that had
been left in place. The heart was then stained with 2.5% Evans
blue to reveal the AAR. TTC staining and infarct sizes were
determined as described for the ex vivo model.
Effects of Long-term OA Treatment on Heart Function in
Streptozotocin-treated Rats (Chronic Hyperglycemia)
We also ascertained the effects of chronic OA treatment within
the diabetic context and its effects on cardiac function. These
studies were completed at the United Arab Emirates University
(Al-Ain, United Arab Emirates). Here diabetes was induced in
male Sprague-Dawley rats by a single intraperitoneal injection of
STZ (60 mg/kg body weight) dissolved in citrate buffer. For OA-
treated rats daily oral gavage was performed with a dose of
60 mg/kg for the entire 2-week period. The OA was made up
Table 1. Body weight and blood glucose levels after 1 week of STZ injection.
% Body weight change Non-fasting blood glucose (mmol/L)
Non-diabetic 8.160.8 6.660.5
STZ-diabetic 24.361.2 27.161.6***
Data are expressed as mean 6 SEM, n $4 in each group.
***p,0.001 vs. non-diabetic control group.
doi:10.1371/journal.pone.0047322.t001
Table 2. Effects of OA on in vivo heart rate, ST height, systolic and diastolic blood pressures during early reperfusion.
Heart rate (beats/minute) Systolic BP (mmHg) Diastolic BP (mmHg)
PI Reperfusion PI Reperfusion PI Reperfusion
ND 404.7616.01 411.768.5 130.968.3 125.369.2 81.5614.1 107.667.4
ND + OA 411.6612.4 399.7615.1 113.6613.9 88.669.5* 87.562.5 62.969.1*
STZ 394.3635.0 429.6620.4 127.468.9 118.468.9 63.364.7 100.863.6
STZ + OA 386.3614.7 391.0617.8 117.465.8 99.065.0* 53.764.5 65.068.0*
ND (non-diabetic); STZ (STZ-diabetic); BP (blood pressure); PI (pre-ischemic). Data are expressed as mean 6 SEM, n $4 in each group).
*p,0.05 vs. respective control.
doi:10.1371/journal.pone.0047322.t002
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freshly on each day and dissolved in DMSO and water. At the end
of the two week period, we determined body weights and fasting
blood glucose levels for all experiments.
Following STZ treatment, rats were killed by decapitation and
hearts rapidly removed, mounted in Langendorff mode and
perfused at a constant flow of 8 ml (g heart)21 min21 at
physiological temperature (36–37uC) with Tyrode solution con-
taining: 140 mM NaCl; 5 mM KCl; 1 mM MgCl2; 10 mM
glucose; 5 mM HEPES; and 1.8 mM CaCl2; adjusted to pH 7.4
with NaOH and continuously bubbled with oxygen. When the
heart rate stabilized, extracellular action potentials were recorded
from the left ventricle in spontaneously beating hearts with a
purpose-built extracellular suction electrode as previously de-
scribed [31]. Here a clip is fixed at the apex of the hanging heart
and a thread tied to the clip. The thread was guided through
pulleys and tied to the force transducer that was connected to the
Power Lab system. Signals from the electrode were collected at
400 Hz, amplified (ML136 Bioamp, ADInstruments, Castle Hill,
New South Wales, Australia) and conveyed via a Powerlab
(PL410, ADInstruments, Castle Hill, New South Wales, Australia)
to a personal computer. Heart functional data are expressed as
force generated (grams).
Western Blot Analysis
Protein isolation was performed as previously described [13].
Briefly, collected heart tissues were homogenized with modified
RIPA buffer, the supernatant centrifuged twice at 4, 300 g for
10 min at 4uC then stored at 280uC until further use. Protein
expression was determined by Western blotting as described
before by us [13,14] for the following antibodies: BAD,
phosphorylated-BAD (Ser 136), caspase-3 (Cell Signaling, MA,
USA), and O-GlcNAc (HBP marker; CTD110.6, Santa Cruz
Biotechnology Inc.). We employed b–actin (Cell Signaling, MA,
USA) as a loading control.
Measurement of Superoxide Dismutase (SOD) Activity
We assessed the total SOD activity (cytosolic and mitochon-
drial components) as detailed in the instructions of a commer-
cially obtained kit (Biovision K 335–100, Mountain View, CA
94043 USA). The assay depends on utilizing a highly water-
soluble tetrazolium salt, WST-1 (2-(4-iodophenyl)-3-(4-nitrophe-
nyl)-5-(2,4-disulfo-phenyl)-2H-tetrazolium, monosodium salt),
which produces a water-soluble formazan dye upon reduction
with a superoxide anion. The rate of WST-1 reduction by
superoxide anion is linearly related to the xanthine oxidase
activity and is inhibited by SOD. Formazan levels can be
measured by absorption with a spectrophotometer at 450 nm.
Briefly, collected heart tissues were homogenized with modified
ice cold RIPA buffer, the supernatant centrifuged twice at 4,
300 g for 10 min at 4uC. The samples were incubated with the
enzyme and WST working solutions at 37uC for 20 min in a 96
well-microtiter-plate (Corning, New York, USA) in an orbital
shaker incubator. Absorbance was read at 450 nm with a
microplate reader (EL 800 KC Junior Universal Microplate
reader, Bio-Tek Instruments Inc, Vermont, USA). SOD activity
Figure 8. Long-term OA treatment improves cardiac function in
STZ-diabetic rats. Sprague-Dawley rats were injected with STZ and
followed for a 2-week period 6 daily OA treatment. Subsequently,
isolated hearts from STZ-diabetic and matched controls were perfused
and action potentials recorded via a force transducer. Values are
expressed as mean 6 SEM (n= 6). **p,0.05 vs. non-diabetic control
and ***p,0.01 vs. respective controls.
doi:10.1371/journal.pone.0047322.g008
Figure 9. OA treatment does not affect pre-ischemic superoxide dismutase and caspase activities. Isolated rat hearts were perfused
under simulated hyperglycemic conditions (33 mM glucose) vs. controls (11 mM glucose) 6100 mM OA treatment. We initially perfused for 60 min,
whereafter OA was added for a further 20 min. Subsequently, the buffer initially used was returned and hearts perfused for an additional 20 min. (A)
Superoxide dismutase activity (% inhibition) in response to high glucose vs. control 6 OA treatment; (B) Caspase activity. Values are expressed as
mean 6 SEM (n= 6).
doi:10.1371/journal.pone.0047322.g009
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was calculated according to the following formula: % inhibitio-
n = (Acontrol–Asample)/Acontrol6100.
Myocardial Superoxide Levels
The heart tissue was pulverized and homogenized in 100
volumes of perchloric acid (10% v/v) and centrifuged for
20 min at 13, 000 g [32]. Protein-free supernatant (0.1 ml) was
subsequently incubated with 0.25 mM lucigenin (Sigma-Aldrich,
St. Louis, MO) at room temperature for 5 min in the dark and
chemiluminescence measured in a white-walled luminometer
96 well-microtiter plate (Corning, New York, USA). Superoxide
levels were expressed as chemiluminescence (RLU) per mg
tissue.
Isolation of Proteins for Carbonylation and Proteasome
Activity Experiments
Heart tissues were cut into small slices and homogenized in 1 ml
of Tris-HCl buffer (pH 7.4) using an IKA Ultra Turrax T25
homogenizer (IKA Labortechnik, Staufen, Germany) and incu-
bated on ice for 10 min before centrifugation at 9, 000 g for
15 min to remove cell debris. The supernatant was used for
protein quantification using the BCA assay.
ELISA Carbonyl Protocol
Protein carbonyls are formed by a variety of oxidative
mechanisms and are sensitive indices of oxidative injury. Protein
carbonylation was determined by the carbonyl ELISA assay
developed in the GEICO laboratory (Universite´ de La Re´union,
Saint Denis de La Re´union, France) based on recognition of
protein-bound DNPH in carbonylated proteins with an anti-DNP
antibody [33].
Here 5 ml of protein from tissue lysates (0.2–0.6 mg) was
denatured by adding 10 ml 12% SDS solution. Subsequently,
proteins were derivatized to DNP hydrazone with 10 ml of DNPH
solution (10 mM in 6 M guanidine hydrochloride, 0.5 M potas-
sium phosphate buffer, pH 2.5). DNPH is a chemical compound
that specifically reacts and binds to carbonylated proteins. Samples
were incubated at room temperature for 30 min and the reaction
was neutralized and diluted in coating buffer (10 mM sodium
carbonate buffer, pH 9.6) to yield a final protein concentration of
0.2–0.6 ng/ml.
Figure 10. Anti-oxidant effects of OA in hearts subjected to ischemia-reperfusion under high glucose perfusion conditions. Isolated
rat hearts were perfused under high glucose conditions vs. controls and subjected to ischemia-reperfusion. For OA treatments groups, 100 mM OA
was added during the first 20 min of reperfusion. (A) Superoxide levels under high glucose conditions vs. control 6 OA treatment; (B) Superoxide
dismutase activity (% inhibition) in response to high glucose vs. control 6 OA treatment; (C) Time course for SOD activity following ischemic insult.
Values are expressed as mean 6 SEM (n= 9). *p,0.05, **p,0.01, ***p,0.001 vs. respective controls.
doi:10.1371/journal.pone.0047322.g010
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Diluted samples were added to wells of a Nunc Immuno Plate
Maxisorp (Dutscher, Brumath, France) and incubated at 37uC for
3 hr, and thereafter washed 5x with PBS/Tween (0.1%) between
each of the following steps: blocking the wells with 1% BSA in
PBS/Tween (0.1%) overnight at 4uC; incubation with anti-DNP
antibody (Sigma-Aldrich, St Louis, MO) (1:2000 dilution in PBS/
Tween [0.1%]/BSA [1%]) at 37uC for 3 hr; incubation with horse
radish peroxidase-conjugated polyclonal anti-rabbit immunoglob-
ulin (GE Healthcare, Mannheim, Germany) (1:4000 dilution in
PBS/Tween [0.1%]/BSA [1%]) for 1 hr at 37uC; addition of
100 ml of TMB substrate solution and incubation for 10 min
before stopping the coloration with 100 ml of 2 M sulphuric acid.
Absorbances were read at 490 nm against the blank (DNP reagent
in coating buffer without protein) with a Fluostar microplate
reader (BMG Labtech, Ortenberg, Germany). Results are
expressed as percentage of absorbance compared to control cells
(treatment of samples with 11 mM glucose) after normalization
with protein concentrations.
Proteasome Activity Measurements
Chymotrypsin-like, trypsin-like, and caspase-like activities of
the proteasome were assayed using fluorogenic peptides (Sigma-
Aldrich, St Louis, MO): Suc-Leu-Leu-Val-Tyr-7-amido-4-
methylcoumarin (LLVY-MCA at 25 mM), N-t-Boc-Leu-Ser-
Thr-Arg-7-amido-4-methylcoumarin (LSTR-MCA at 40 mM)
and N-Cbz-Leu-Leu-Glu-b-naphthylamide (LLE-NA at
150 mM), respectively [34]. Assays were performed with
,50 mg of protein lysate (in 25 mM Tris–HCl [pH 7.5]) and
the appropriate substrate that were incubated together for 0–
30 min at 37uC. Aminomethylcoumarin and b-naphthylamine
fluorescence were measured at excitation/emission wavelengths
of 350/440 and 333/410 nm, respectively, using a Fluostar
fluorometric microplate reader (BMG Labtech, Ortenberg,
Germany). Peptidase activities were measured in the absence/
presence of 20 mM of the proteasome inhibitor, MG132 (N-Cbz-
Leu-Leu-leucinal), and the difference between the two values was
attributed to proteasome activity. Data were normalized to
protein concentrations.
Statistical Analysis
Data are presented as mean 6 standard error of mean (SEM).
Statistical analysis was performed by the Mann Whitney t-test, or
one way analysis of variance (ANOVA) and Tukey –Kramer
(GraphPad Prism). Values were considered significant when
p,0.05.
Figure 11. OA treatment decreases carbonylation levels in hearts subjected to ischemia-reperfusion under high glucose conditions.
Isolated rat hearts were perfused under high glucose conditions vs. controls and subjected to ischemia-reperfusion. For OA treatments groups,
100 mM OA was added during the first 20 min of reperfusion. (A) Degree of carbonylation under high glucose conditions vs. control; (B) OA treatment
at baseline (11 mM glucose) and (C) under high glucose conditions (33 mM). Values are expressed as mean 6 SEM (n= 9). ***p,0.001 vs. respective
controls.
doi:10.1371/journal.pone.0047322.g011
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Results
Isolation of OA from Clove Extract
Evaluation of one-dimensional 1H- and 13C-NMR spectra of
the isolated OA compound confirmed the presence of the 48
hydrogen and the 30 carbon atoms present in the molecule (data
not shown). For the determination of complex components within
the molecule, two- dimensional 1H- and 13C-NMR spectra was
conducted and confirmed the chemical structure of OA (data not
shown).
Effects of OA Treatment on ROS Levels and Apoptosis in
Heart Cells
We employed both fluorescence microscopy and flow cytomet-
ric analysis to evaluate whether OA acts as an anti-oxidant under
in vitro simulated chronic hyperglycemic conditions. Our data show
significantly increased ROS levels in heart cells that were cultured
under high glucose conditions (Figure 1). However, OA treatment
(acute and chronic) significantly decreased myocardial ROS levels
under control and high glucose conditions. Here even the lower
OA dose (20 mM) blunted the increase in ROS levels under high
glucose culturing conditions (p,0.05 vs. untreated high glucose
cells) (Figure 1).
To examine whether OA exhibits anti-apoptotic effects, H9c2
cells were treated with 20 mM and 50 mM OA, respectively, for
24 hr. Our data revealed increased caspase-3 activity in response
to high glucose culturing conditions (p,0.05 vs. 5.5 mM glucose
group) (Figure 2). The low glucose-treated cells also exhibited a
dose-dependent reduction in caspase-3 enzymatic activity, i.e. by
28.462.2% and by 43.761.5%, respectively, for the 20 mM and
50 mM OA doses (p,0.001 vs. 5.5 mM glucose group). Likewise,
high glucose-treated cells displayed a decrease, i.e. by 19.960.8%
and by 43.463.4%, respectively, for the 20 mM and 50 mM OA
doses (p,0.001 vs. 33 mM glucose control) (Figure 2). Our results
at the 6 hr time point revealed similar findings (data not shown).
In support, flow cytometric analysis (Annexin V/FITC PI) showed
decreased apoptosis in H9c2 cells exposed to high glucose and
treated with 100 mM OA for 6 hr (p,0.01) (Figure 3). After 24 hr
the decrease was observed under both low (p,0.001 vs. control)
and high glucose (p,0.001 vs. control; p,0.001 vs. high glucose
without OA treatment) culturing conditions (Figure 3).
Evaluation of ex vivo Heart Function during Global
Ischemia-reperfusion (Simulated Acute Hyperglycemia)
The functional data for both low and high glucose perfusions
(without ischemia) showed no significant differences with OA
treatment (Figure 4). However, perfusion data with global
Figure 12. Anti-apoptotic effects of OA in hearts subjected to ischemia-reperfusion under high glucose conditions. Isolated rat hearts
were perfused under high glucose conditions vs. controls and subjected to ischemia-reperfusion. For OA treatments groups, 100 mM OA was added
during the first 20 min of reperfusion. (A) Caspase activity; (B) p-BAD/BAD peptide levels; (C) Caspase-3 peptide levels; (D) Time course of myocardial
apoptosis following the ischemic insult. Values are expressed as mean 6 SEM (n = 9). *p,0.05, **p,0.01, ***p,0.001 vs. respective controls.
doi:10.1371/journal.pone.0047322.g012
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ischemia and reperfusion show that LVDP recovery for hearts
perfused with high glucose was markedly lower compared to the
control group (p,0.01 vs. 11 mM control), ranging between
12.763.2% and 23.160.9% of the baseline pre-ischemic values
during reperfusion (Figure 5). By contrast, the control group’s
functional recovery during reperfusion ranged from ,28 to 50%
of the baseline pre-ischemic value. Our perfusion data revealed
that OA treatment markedly improved functional recovery of high
glucose perfused hearts during reperfusion (p,0.001 vs. untreated
high glucose), i.e. to 6268% of the baseline pre-ischemic value
(Figure 5B). In agreement, OA treatment enhanced dP/dtmax (data
not shown) and RPP for the high glucose perfused group while it
resulted in no significant effects for baseline treated hearts
(Figure 5). Moreover, the regional ischemia-reperfusion experi-
ments show that OA treatment of high glucose perfused hearts
decreased the infarct size from 59.663.1% to 38.761.6% (p,0.01
vs. high glucose untreated) (Figure 6). We also performed
additional experiments with 11 mM and 33 mM mannitol and
found no significant effects on functional recovery of hearts
following global ischemia-reperfusion, thus ruling out any osmotic
effects (data not shown).
In vivo Coronary Artery Ligations in Streptozotocin-
treated Rats (Chronic Hyperglycemia)
We next evaluated the cardioprotective effects of OA treatment
within the in vivo context, i.e. by employing coronary artery
ligations in STZ-treated hyperglycemic rats. Our data revealed
markedly elevated blood glucose levels in STZ-diabetic rats
compared to matched controls (p,0.001) (Table 1). This was
associated with decreased weight gain in the STZ-diabetic rats. In
agreement with our ex vivo perfusion data, we found that infarct
size was significantly increased for the STZ-treated rats versus
controls (47.562.9% vs. 27.965.2%) following 30 min coronary
artery ligation (Figure 7). Moreover, this effect was blunted by OA
treatment. There were no differences in the area at risk amongst
all the groups (data not shown). OA administration also decreased
systolic and diastolic blood pressures in STZ-diabetic rats vs.
untreated STZ-diabetic controls during the early reperfusion
period, i.e. within the first twenty minutes of reperfusion (Table 2).
There were no significant differences on heart rate and systolic/
diastolic blood pressures before regional ischemia for all the groups
(Table 2).
Figure 13. OA treatment attenuates O-GlcNAcylation in hearts subjected to ischemia-reperfusion under high glucose conditions.
Isolated rat hearts were perfused under high glucose conditions vs. controls and subjected to ischemia-reperfusion 6 OA treatment during
reperfusion. Western blot analysis for overall O-GlcNAcylation is shown with b–actin as loading control. Densitometric analysis for O-GlcNAcylation is
displayed below gel image (normalized to corresponding b–actin values). Values are expressed as mean 6 SEM (n= 6). *p,0.05, **p,0.01 vs.
respective controls.
doi:10.1371/journal.pone.0047322.g013
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Effects of Long-term OA Treatment on Heart Function in
Streptozotocin-treated Rats (Chronic Hyperglycemia)
To assess the effects of long-term OA treatment on heart
function, rats were injected with STZ and followed for 2 weeks 6
daily OA treatment. STZ treatment markedly increased fasting
blood glucose (16.360.8 mmol/L) versus matched controls
(5.460.3 mmol/L) (p,0.01). Our data show that the force
generated by STZ-diabetic rat hearts was significantly lower
compared to non-diabetic controls (p,0.01) (Figure 8). However,
chronic OA treatment for two weeks significantly improved
cardiac function in STZ-diabetic rats.
Effects of OA Treatment on ex vivo Myocardial ROS Levels
and Apoptosis
To confirm our in vitro data, we next evaluated whether OA
exhibits anti-oxidant and anti-apoptotic properties within an ex vivo
context. Under pre-ischemic conditions OA treatment did not
significantly affect myocardial SOD activity or apoptosis (Figure 9).
However, following ischemia OA administration blunted high
glucose-induced myocardial superoxide levels and concomitantly
upregulated SOD activity (Figure 10A and 10B). To gain further
insight into temporal effects, we also performed analyses imme-
diately after ischemia and for several time points thereafter. These
data show that OA exerts its main anti-oxidant effects within the
first 20 minutes following ischemia, whereafter it is sustained
(Figure 10C). We largely confirmed these data by evaluating the
degree of protein carbonylation as an additional marker of
oxidative stress (Figure 11). However, the OA-induced decrease in
protein carbonylation under high glucose conditions did not reach
statistical significance (p = 0.076 vs. untreated high glucose)
(Figure 11C).
We next assessed anti-apoptotic effects of OA in ex vivo perfused
heart tissues. Myocardial caspase activity levels were increased
under high glucose perfusion conditions (p,0.001 vs. untreated
control). This effect was attenuated by OA treatment (p,0.01 vs.
untreated high glucose) (Figure 12A). In agreement, OA treatment
significantly increased cardiac p-BAD/BAD and decreased
caspase-3 peptide levels under high glucose perfusion conditions
(Figure 12B and 12C). We also investigated the temporal nature of
myocardial apoptosis following ischemia. Our data show that anti-
apoptotic effects emerge at the 40 minute time point, suggesting
that these effects occur as a result of the earlier upstream reduction
of oxidative stress (Figure 12D).
To evaluate whether OA mediates its anti-apoptotic effects via
HBP modulation, we next determined the overall degree of O-
GlcNAcylation in our experimental system. Our data show
increased O-GlcNAcylation in response to high glucose exposure
(p,0.05 vs. untreated high glucose) that was significantly
decreased by OA treatment (Figure 13).
Figure 14. Increased proteasomal activity in hearts subjected to ischemia-reperfusion under high glucose conditions. Isolated rat
hearts were perfused under high glucose conditions vs. controls and subjected to ischemia-reperfusion. A) Trypsin-like proteasomal, (B)
chymotrypsin-like, and (C) caspase-like activities after 60 min of reperfusion under high glucose conditions (33 mM) vs. control (11 mM). Values are
expressed as mean 6 SEM (n= 9). *p,0.05, **p,0.01 vs. respective controls.
doi:10.1371/journal.pone.0047322.g014
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Evaluating the Effects of OA Treatment on Myocardial
Proteasomal Activity in Hearts Subjected to Ischemia-
reperfusion under High Glucose Conditions
We initially evaluated post-ischemic proteasomal activities
under high glucose perfusion conditions. Here we found that all
proteasomal activities were markedly induced in high glucose
perfused hearts following ischemia-reperfusion (Figure 14). For
11 mM glucose perfusions, OA treatment decreased chymo-
trypsin-like proteasomal activity compared to the untreated
control (p,0.05), but did not result in any significant effects on
trypsin-like and caspase-like proteasomal activities (Figure 15A,
B, C). Furthermore, OA treatment significantly diminished
trypsin-like and chymotrypsin-like proteasomal activities in high
glucose exposed rat hearts (Figure 15D and 15E). However, it
had no effect on caspase-like activity in these hearts (Figure 15F).
Discussion
The damaging alliance between hyperglycemia and myocardial
infarctions necessitates the development of novel therapeutic
interventions that offer cardioprotection within this context.
Moreover, stress-induced hyperglycemia in non-diabetic patients
suffering an acute myocardial infarction also results in damaging
outcomes, e.g. increased in-hospital mortality [7,8]. For the
current study we explored whether OA acts as a novel
cardioprotective factor in response to ischemia-reperfusion under
hyperglycemic conditions. We tested our hypothesis by employing
cell culture studies, ex vivo and in vivo rat heart perfusion models,
and long-term OA treatment of diabetic rats as experimental
systems. The main findings of this study are that OA treatment
results in cardioprotection for rat hearts by attenuating hypergly-
cemia-induced oxidative stress, apoptosis, and proteasomal activity
following ischemia-reperfusion.
We initially investigated our hypothesis by exposing isolated rat
hearts to ischemia-reperfusion and found a marked decline in
contractile function under high glucose perfusion conditions
(simulated acute hyperglycemia). However, OA treatment resulted
in a striking increase in functional recovery and demonstrates, for
the first time as far as we are aware, that it triggers cardioprotec-
tion in high glucose perfused rat hearts. Our infarct size data
further corroborated these findings. Moreover, OA administration
following in vivo coronary artery ligations in hyperglycemic rats
also decreased infarct sizes in the STZ-diabetic rats. Although OA-
mediated cardioprotection was previously reported following
ischemia-reperfusion, such studies were performed on hearts
isolated from rats that were pre-treated with OA for several days
[22,35]. Furthermore, these experiments were completed under
normoglycemic perfusion conditions. We also performed experi-
ments for long-term OA treatment and found that it restored heart
function in isolated rat heart perfusions. Collectively, our data
therefore demonstrate that OA treatment initiated after an
ischemic insult elicited cardioprotection, thus meaning that our
findings may offer therapeutic value to actual clinical settings
(versus pre-treatments).
To gain further insight into underlying mechanisms responsible
for OA-mediated cardioprotection, we next evaluated whether it
Figure 15. OA attenuates high glucose-induced proteasomal activity following ischemia-reperfusion. Isolated rat hearts were perfused
under high glucose conditions vs. controls and subjected to ischemia-reperfusion. For OA treatments groups, 100 mM OA was added during the first
20 min of reperfusion. (A) Trypsin-like proteasomal, (B) chymotrypsin-like, and (C) caspase-like activities after 60 min of reperfusion at baseline
(11 mM glucose). (D) Trypsin-like proteasomal, (E) chymotrypsin-like, and (F) caspase-like activities after 60 min of reperfusion under high glucose
conditions (33 mM glucose). Values are expressed as mean 6 SEM (n= 9). *p,0.05 vs. respective controls.
doi:10.1371/journal.pone.0047322.g015
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displays anti-oxidant and anti-apoptotic properties in our exper-
imental systems. Here we found that OA diminished high glucose-
induced myocardial oxidative stress and apoptosis in both our in
vitro and ex vivo experimental models. Moreover, our ex vivo data
show significantly elevated superoxide levels together with
decreased SOD activity in simulated acute hyperglycemic hearts
following an ischemic insult. How does OA exert its anti-oxidant
effects in hyperglycemic hearts exposed to ischemia-reperfusion?
Although the precise mechanisms of OA-mediated anti-oxidant
effects are unclear, earlier data support a direct scavenging role,
i.e. by decreasing superoxide and hydrogen peroxide levels
together with reduced lipid peroxidation [20,36]. Here OA (a
lipophilic compound) is proposed to intercalate into the lipid
matrix and stabilize myocardial cell membranes under stressful
conditions [37]. In addition, OA contains a single phenolic
hydroxyl group that is likely to be the bioactive group for
scavenging free radicals [38]. Our time course studies suggest that
this likely occurs quite rapidly after an ischemic insult, peaking at
about 20 minutes and thereafter sustained up to at least 60 minutes
post-ischemia.
Previous studies established that OA treatment also results in
transcriptional effects that increase expression of several anti-
oxidant defense genes, including a-tocopherol, glutathione perox-
idase, catalase, thioredoxin peroxidase and superoxide dismutase
[35,38–42]. Higher gene expression in this case is probably
mediated by MAP kinases (JNK and ERK) that may regulate
target transcriptional modulators [39]. The basic leucine zipper
transcription factor, nuclear factor erythroid 2 p45-related factor 2
(Nrf2), is strongly implicated in this process [39]. Nrf2 plays a key
role in protecting cells from oxidative stress by binding anti-
oxidant-response elements (ARE) of gene promoters to induce
expression of numerous target genes, e.g. glutathione peroxidase,
heme oxygenase, and thioredoxin [43–45]. Earlier work deter-
mined that OA upregulated Nrf2 expression in hepatocytes, with
MAPK activation implicated in this process [39]. Furthermore,
Ichikawa et al. [46] found that dh404 (novel OA derivative)
increased Nrf2 translocation to the nucleus to enhance Nrf2-
driven transcription and suppress oxidative stress in H9c2
cardiomyoblasts. Collectively these data show that OA acts as an
anti-oxidant and that its effects are mediated both by a direct
scavenging role and also by induction of various anti-oxidant
defense genes.
We propose that the improved functional effects detected with
OA treatment stems in part from its anti-apoptotic effects observed
in both our experimental models, that likely occur downstream of
elevated oxidative stress. There are several ways how this may
happen. Firstly, rat hearts exposed to high glucose displayed
increased superoxide and nitric oxide generation that favors the
production of peroxynitrite and nitrotyrosine with damaging
consequences [47]. For example, others found that peroxynitrite
inhibits the mitochondrial respiratory chain [48,49] and triggers
myocardial apoptosis [50]. Our time course studies support the
concept that myocardial apoptosis occurs downstream of the initial
post-ischemic oxidative stress burst. Here we found that myocar-
dial apoptosis in high glucose perfused hearts only increased from
the 40th minute after the ischemic insult.
Secondly, our data show that OA exerts cardioprotective effects
by attenuating HBP flux in hyperglycemic rat hearts. These data
are in agreement with previous work from our laboratory that
established that hyperglycemia results in greater oxidative stress,
increased BAD O-GlcNAcylation and BAD-Bcl-2 dimer forma-
tion, thereby mediating HBP-induced myocardial apoptosis in
H9c2 cardiomyoblasts [13]. Thirdly, it is also possible that the
OA-mediated decrease in oxidative stress may also limit hyper-
glycemia-induced inactivation of the sarco/endoplasmic reticulum
Ca2+-ATPase [51] and electrophysiological alterations (arrhyth-
mias, QT prolongation) [47,52,53]. Thus our study shows that OA
exerts anti-oxidant effects that attenuate myocardial apoptosis and
thereby improve contractile functional recovery following ische-
mia-reperfusion of hyperglycemic rat hearts.
Our ex vivo pre-ischemic data suggest that the cardioprotective
effects of OA are not dependent on any inherent inotropic effects,
but rather involve anti-oxidant and anti-apoptotic mechanisms.
The potent hypotensive properties of OA confirm previous
observations in Dahl salt sensitive [23] and STZ-diabetic rats
[21]. These data therefore offer significant clinical promise
considering that hypertension is a robust risk factor for diabetes-
induced CVD and non-diabetic heart diseases. The mechanisms
underlying this interesting phenomenon were, however, not
elucidated in this study. It is possible that OA treatment may
also act to modulate the nervous system, but further studies are
required to prove this.
We next investigated the role of the UPS in hyperglycemic
hearts exposed to ischemia-reperfusion since it is the major non-
lysosomal pathway for degradation of ubiquinated proteins [54].
We reasoned that since UPS dysregulation occurs during
ischemia-reperfusion, it may be an important contributing factor
to reduced contractile function found under these conditions [54].
However, conflicting data have been published with both
inhibition and activation of the UPS linked to improved heart
function in response to ischemia–reperfusion [reviewed in 55,56].
It is likely that the discordant data may be due to differences in
experimental models and protocols employed. We detected
diminished proteasomal activities in 11 mM perfused rat hearts
following ischemia (versus pre-ischemic hearts) (data not shown).
By contrast, high glucose perfused hearts exhibited a robust
upregulation of trypsin-like, chymotrypsin-like and caspase-like
proteasomal activities following ischemia (Figure 8). We propose
that ischemia-reperfusion together with hyperglycemia trigger
greater oxidative stress that may result in increased misfolded
proteins that are targeted for removal by UPS degradation.
However, excessively high UPS activation may result in the
activation of damaging signaling pathways, e.g. nuclear factor-
kappa B (NFkB) [10]. Here greater UPS activity will degrade IkB
(NFkB inhibitor) and release unbound NFkB to the nucleus to
induce expression of various genes that may exacerbate inflam-
mation and reperfusion injury [57,58]. In support of this concept,
Pye et al. [16] ascertained that proteasomal inhibition blunted
NFkB activation during reperfusion, thereby resulting in de-
creased reperfusion injury. Moreover, hyperglycemic rats treated
with bortezomib (protease inhibitor) exhibited diminished UPS,
inflammation and myocardial damage in response to ischemia-
reperfusion [10]. In agreement, we found that OA treatment
attenuated proteasomal activities in high glucose hearts following
ischemia-reperfusion. Together our data show that hearts exposed
to high glucose levels and subjected to ischemia-reperfusion
display UPS overactivity that may impair the heart’s functional
recovery. Moreover, we established that OA treatment inhibits the
UPS and that this is linked with improved cardiac contractile
function following ischemia-reperfusion under simulated hyper-
glycemic conditions.
How do our data differ from previous studies that implicate
glucose-insulin-potassium (GIK) in cardioprotection? We propose
that the protective effects of GIK largely depend on the actions of
insulin i.e. via a) its direct cardioprotective (anti-apoptotic) effects
[58–61] and b) its glucose lowering abilities. It is well established
that insulin administration should increase plasma glucose
clearance thus limiting damaging effects of acute and chronic
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hyperglycemia (‘glucotoxicity’). Moreover, insulin promotes glu-
cose uptake and the generation of glycolytic ATP that is linked
with cardioprotection [61]. GIK treatment has resulted in mixed
success, e.g. treatment of patients with acute myocardial infarction
(CREATE-ECLA trial) did not result in any significant cardio-
protective effects [62]. Here it is proposed that the potential
protective effects of GIK may have been abolished by higher blood
glucose levels in GIK-treated patients [58]. Finally, a recent study
investigating glucose-insulin treatment in patients undergoing
coronary artery bypass grafting (but while maintaining normogly-
cemia) found that it was cardioprotective and improved myocar-
dial function [63]. Together these data strongly indicate that
insulin acts as the major protective component of GIK, and that
higher blood glucose levels are in fact damaging to the
cardiovascular system.
In summary, this study demonstrates that OA acts as a novel
cardioprotective agent in hearts exposed to high glucose levels by
decreasing oxidative stress, reducing apoptosis and the UPS,
leading to cardioprotection following ischemia-reperfusion. These
data are promising since it may eventually result in novel
therapeutic interventions to treat stress-induced acute hyperglyce-
mia (in non-diabetic patients) and also diabetic patients with
associated CVD complications, e.g. acute myocardial infarction.
We are of the opinion that this is particularly relevant within the
developing world context, where it may provide a cost-effective
therapeutic intervention for the treatment of acute myocardial
ischemia in these individuals.
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